肺栓塞 中国就医指南

Pulmonary embolism (PE) is a life-threatening cardiovascular emergency characterized by the obstruction of one or more pulmonary arteries—typically by thrombi originating from deep veins of the lower extremities or pelvis (deep vein thrombosis, DVT). This acute vascular occlusion impairs gas exchange, increases pulmonary vascular resistance, and can precipitate right ventricular strain, hemodynamic instability, and sudden death. Pathogenesis centers on Virchow’s triad: venous stasis (e.g., immobility, post-surgery), endothelial injury (e.g., trauma, catheterization), and hypercoagulability (e.g., inherited thrombophilias like Factor V Leiden, acquired conditions such as cancer, pregnancy, or antiphospholipid syndrome). In hematologic practice, PE is closely linked to underlying blood disorders—including myeloproliferative neoplasms (e.g., polycythemia vera, essential thrombocythemia), paroxysmal nocturnal hemoglobinuria (PNH), and antithrombin/protein C/S deficiencies—which significantly elevate thrombotic risk. Epidemiologically, PE affects approximately 1–2 per 1,000 individuals annually worldwide; in China, incidence is estimated at 25–40 cases per 100,000 person-years, with rising detection due to improved imaging and heightened clinical awareness. Mortality remains substantial: untreated massive PE carries >30% mortality, while even diagnosed and treated PE has a 30-day all-cause mortality of 8–12%. Key modifiable risk factors include prolonged immobilization (>72 hours), major surgery (especially orthopedic or abdominal), active malignancy, hormone therapy (including oral contraceptives), obesity (BMI ≥30), and advanced age (>65 years). Non-modifiable risks include prior VTE, inherited thrombophilia, and certain autoimmune conditions. Quality of life impact is profound and often underrecognized: survivors frequently experience chronic dyspnea, exercise intolerance, anxiety, depression, and post-thrombotic syndrome-like symptoms—even in the absence of overt chronic thromboembolic pulmonary hypertension (CTEPH). Up to 40% report persistent functional limitations at 6 months, and fatigue and cognitive fog are common sequelae affecting work capacity, social engagement, and daily self-care. Early diagnosis via D-dimer testing, CT pulmonary angiography (CTPA), or V/Q scanning—and prompt initiation of anticoagulation—is critical. Hematology departments play a pivotal role in identifying underlying prothrombotic hematologic disorders, guiding long-term anticoagulant selection (e.g., DOACs vs. warfarin), managing bleeding complications, and coordinating multidisciplinary care with pulmonology, cardiology, and interventional radiology.

# 肺栓塞（血液科）治疗方案与费用明细（人民币/RMB）

一、非手术/药物治疗（一线首选）

适用人群：低-中危患者（PESI≤10、无休克/低血压、右心功能正常）

• •抗凝治疗（≥3个月）：

- 依诺肝素（皮下注射）+华法林过渡：¥600–¥1,500/月（含INR监测¥30/次，每月4次）

• •检查费：D-二聚体（¥80）、CTPA（¥800–¥1,200）、下肢静脉超声（¥300）、血气分析（¥120）、凝血四项（¥150）

二、介入/手术治疗（高危/溶栓禁忌/失败者）

适用人群：高危PE（伴休克/持续低血压）、溶栓禁忌或失败、右心负荷进行性加重

• •肺动脉导管碎栓+抽吸术（微创介入）：¥35,000–¥68,000（含DSA引导、耗材、麻醉）
• •外科肺动脉血栓内膜剥脱术（PEA）：¥120,000–¥180,000（限具备心肺外科资质的三甲医院，含ICU监护7天）
• •术前必查：CTPA（¥1,200）、右心超声（¥450）、肺功能+6分钟步行（¥600）、BNP/NT-proBNP（¥200）

三、特殊复杂情况处理

• •慢性血栓栓塞性肺高压（CTEPH）：靶向药物（马昔腾坦¥3,200/月；安立生坦¥2,600/月）+长期随访（年均检查费¥4,500）
• •恶性肿瘤相关PE：LMWH维持（达肝素钠¥1,800/月）+多学科会诊（¥500/次）

方案快速选择指南

✅ 预算有限/初发轻症：利伐沙班仿制药+基础检查（总首年≈¥5,000） ✅ 高龄/出血风险高：依诺肝素过渡+严密监测（首年≈¥8,000） ✅ 高危休克/溶栓失败：立即转介入中心行导管取栓（单次总费用≈¥50,000） ✅ 确诊CTEPH：转呼吸/心内科联合评估PEA或靶向治疗（首年综合支出¥60,000–¥150,000）